BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34233544)

  • 1. Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone.
    Parisi S; Napoli I; Lillo S; Cacciola A; Ferini G; Iatì G; Pontoriero A; Tamburella C; Davì V; Pergolizzi S
    J Oncol Pharm Pract; 2022 Jan; 28(1):237-241. PubMed ID: 34233544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
    Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of computed tomography (CT) and 18F-deoxyglucose-coincidence detection emission tomography (FDG-CDET) image fusion for optimisation of conformal radiotherapy in non-small-cell lung cancers].
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Cancer Radiother; 2005 Sep; 9(5):304-15. PubMed ID: 16087377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Dall'Olio FG; Calabrò D; Conci N; Argalia G; Marchese PV; Fabbri F; Fragomeno B; Ricci D; Fanti S; Ambrosini V; Ardizzoni A
    Eur J Cancer; 2021 Jun; 150():99-107. PubMed ID: 33892411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
    Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
    Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report.
    Ni J; Yang L; Zhu H; Chu M; Zhang C; Zhao W; Yang M; Xu X; Zheng E; Jiang X; Li R; Zhao G
    Ann Palliat Med; 2021 Apr; 10(4):4999-5009. PubMed ID: 33966436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
    Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. True abscopal effect in a patient with metastatic non-small cell lung cancer.
    Vilinovszki O; Andratschke N; Huellner M; Curioni-Fontecedro A; Kroeze SGC
    Radiat Oncol; 2021 Oct; 16(1):194. PubMed ID: 34600561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Schonewolf CA; Verma V; Post CM; Berman AT; Frick MA; Vachani A; Lin C; Simone CB
    Lung Cancer; 2018 Mar; 117():53-59. PubMed ID: 28800837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET).
    Erdi YE; Rosenzweig K; Erdi AK; Macapinlac HA; Hu YC; Braban LE; Humm JL; Squire OD; Chui CS; Larson SM; Yorke ED
    Radiother Oncol; 2002 Jan; 62(1):51-60. PubMed ID: 11830312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.
    van den Heuvel MM; Verheij M; Boshuizen R; Belderbos J; Dingemans AM; De Ruysscher D; Laurent J; Tighe R; Haanen J; Quaratino S
    J Transl Med; 2015 Jan; 13():32. PubMed ID: 25622640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer.
    Vanuytsel LJ; Vansteenkiste JF; Stroobants SG; De Leyn PR; De Wever W; Verbeken EK; Gatti GG; Huyskens DP; Kutcher GJ
    Radiother Oncol; 2000 Jun; 55(3):317-24. PubMed ID: 10869746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Systemic Therapy Type and Timing on Intracranial Tumor Control in Patients with Brain Metastasis from Non-Small-Cell Lung Cancer Treated With Stereotactic Radiosurgery.
    Singh SA; McDermott DM; Mattes MD
    World Neurosurg; 2020 Dec; 144():e813-e823. PubMed ID: 32956881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
    Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Induction chemotherapy followed by concomitant combined radiotherapy and chemotherapy in stage III non-small cell bronchial carcinoma].
    Bouillet T; Morère JF; Mazeron JJ; Piperno-Neuman S; Boaziz C; Haddad E; Breau JL
    Cancer Radiother; 1997; 1(2):121-31. PubMed ID: 9273182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.